Aims: Examine the association between obesity and glycemic control among patients with type 1 (T1DM) or type 2 diabetes mellitus (T2DM). Methods: Data from US physician electronic health records (Humedica®) from 2009-2011 were utilized. Patients were defined as having above-target glycemic control if they had an HbA1c ≥7% at any time during the study period. Multinomial logistic regressions were conducted separately for T1DM and T2DM patients, and examined associations between BMI categories and probability of having above-target glycemic control (≥7% and b 8%, ≥8% and b 9%, or ≥9%) while controlling for patient demographics, general health, comorbid conditions, and antihyperglycemic medication use. Results: There were 14,028 T1DM and 248,567 T2DM patients; 47.8% of T1DM and 63.4% of T2DM were obese (BMI ≥30 kg/m 2 ). For T1DM, being overweight (BMI 25-b 30), obese class I (30-b 35), II (35-b 40), or III (≥40) was associated with a significantly higher probability of having HbA1c ≥ 8% and b9% or ≥9%, while being overweight was associated with a significantly higher probability of having HbA1c ≥7% and b8% compared to normal BMI (BMI ≥ 18.5 and b 25). For T2DM patients, being overweight, obese class I, II, or III was associated with a significantly higher probability of having HbA1c ≥7% and b 8%, ≥8% and b 9%, or ≥9%. Conclusions: For both T1DM and T2DM patients, there were positive and statistically significant associations between being overweight or obese and having suboptimal glycemic control. These findings quantify the associations between obesity and glycemic control, and highlight the potential importance of individual characteristics on glycemic control.
Introduction
Diabetes mellitus currently affects 29.1 million Americans (Centers for Disease Control and Prevention, 2014b ) and the United States (US) economy with $245 billion (2012) in treatment costs each year (American Diabetes Association, 2013) . Obesity is also highly prevalent in the US, with more than one-third of the adult population classified as obese, indicated by a body mass index (BMI kg/m 2 ) of 30 or above (Centers for Disease Control and Prevention, 2014a) . Being overweight or obese independently increases the risks of developing a large number of serious illnesses, including coronary heart disease, some cancers, stroke, liver and gallbladder disease, and osteoarthritis (Centers for Disease Control and Prevention, 2013; Hubert, Feinleib, McNamara, & Castelli, 1983 ; National Institutes of Health and National Heart, Lung, and Blood Institute, 1998) . Because of these obesityassociated conditions, obese Americans have 42% higher yearly health care costs relative to those of normal weight, and the aggregate costs of obesity in the US have been estimated at $147 billion (2008 dollars) annually, or 9.1% of all medical spending (Finkelstein, Fiebelkorn, & Wang, 2003) . The prevalence of obesity in the US has risen significantly over the past several decades (Centers for Disease Control and Prevention, 2014a ) and has been a major driver of the nation's rapidly increasing health care costs (Finkelstein et al., 2003) .
Excess body weight has been identified as an issue of concern for both type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM). Obesity is a major risk factor for T2DM, (Ganz et al., 2014) and 80% of individuals with T2DM are overweight or obese (National Institutes of Health and National Institute of Diabetes and Digestive and Kidney Disease, 2004) . Among patients with T2DM, obesity raises the odds of developing many common diabetic complications, including heart disease, retinopathy, dyslipidemia, and hypertension (American Diabetes Association, 2014) . Previous studies have shown that the glycemic control of patients with T2DM tends to worsen with weight gain and to improve with weight loss, (Neiberg et al., 2012; Shantha, Kumar, Kahan, & Cheskin, 2012 ) while significant weight loss, such as that associated with gastric bypass surgery, has been shown to lead to a partial or total remission of T2DM (Scopinaro et al., 2014) . Among individuals with T1DM, research has shown a 7-fold increase in the prevalence of obesity among patients with T1DM after 18-years follow up, with the amount of insulin used positively associated with weight gain (Conway et al., 2010) . Furthermore, clinical trial evidence shows that weight gain among patients with T1DM is associated with an increased cardiovascular risk (Purnell et al., 1998) and that this risk is lower among patients with improved glycemic control (Williams, Erbey, Becker, & Orchard, 1999) .
In addition to the research which has examined the relationship between glycemic control and changes in weight, there has been some research which has focused on the relationship between BMI categories and glycemic control. For example, a study using data from the National Health and Nutrition Examination Survey (NHANES) between 1999 and 2006 showed that mean HbA1c levels were highest for diabetes patients with BMI b 25 (Nguyen, Nguyen, Lane, & Wang, 2011) . However, little research has focused on the relationship between BMI classifications and HbA1c among a large, insured population.
The goal of this research was to improve understanding of the association between obesity and glycemic control. Specifically, the analyses used a large, cross-national population of individuals with T1DM and T2DM to examine the association between BMI classes and the odds of having suboptimal glycemic control, as indicated by a hemoglobin A1c (HbA1c) value higher than b7%, given that such a target has been defined as reasonable for many non-pregnant adults (American Diabetes Association, 2014). Furthermore, the analyses examines a range of above target glycemic control (HbA1c ≥ 7% and b8%, ≥ 8% and b9%, and ≥9%) and also identifies other factors linked to suboptimal glycemic control.
Methods
An electronic health record (EHR) data base (Humedica®) was analyzed. The data were extracted from various health information technology systems in medical group practices and integrated delivery networks (IDNs), and contain laboratory results, radiology and pathology reports, physician and nurse notes, prescriptions written and dispensed, procedures, diagnoses, and other details of a patient's office visit. Humedica data are based upon a network of provider organizations that treat approximately 30 million patients who may be uninsured or insured via commercial insurance, Medicare, or Medicaid. The data come from 38 states, although the midwestern region of the US is overrepresented. The data are all de-identified and fully comply with Health Insurance Portability and Accountability Act (HIPAA) regulations.
To be included in this study, an individual was first identified as having T1DM or T2DM between January 1, 2009 and December 31, 2011. Patients were classified as having T1DM if they received at least two diagnoses of T1DM (250.x1 or 250.x3) during the study period and were classified as having T2DM if they received at least two diagnoses of T2DM (250.x0 or 250.x2) and were not in the T1DM cohort. Individuals were also required to have at least one BMI value and one HbA1c value recorded during this time period, and to be at least age 18 years in the year 2009. Individuals were excluded if they were diagnosed as pregnant at any time in the 3-year time period or if their first active record was after January 2009 or their last active record was before December 2011. Finally, patients identified as underweight were excluded since they represented less than 1% of the patients. These inclusion/exclusion criteria resulted in a sample size of 259, 595 (248, 567 with T2DM and 14, 028 with T1DM) . Fig. 1 illustrates how each inclusion/exclusion criterion affected sample size.
Descriptive statistics (mean and standard deviation or medians and interquartile ranges for continuous variables, and frequency and percentages for categorical variables) were used to characterize the sample. Student's t-tests and chi-square tests were used to assess differences between cohorts based upon glycemic control. Glycemic control was measured as the highest recorded HbA1c over the study period and patients were categorized into four groups depending upon whether their HbA1c was b7%, ≥ 7% and b 8%, ≥8% and b 9%, or ≥ 9%. These cutoffs were based upon clinical guidelines which recommend a treatment target of HbA1c b7% for many non-pregnant adults with diabetes and suggest that a target of b 8% may be appropriate for patients with a history of severe hypoglycemia, limited life expectancy, or diabetic complications or comorbidities (American Diabetes Association, 2015) . Furthermore, results from an observational study among the elderly suggest that a target HbA1c of 8 to 8.9% may be appropriate (Yau et al., 2012) and that an HbA1c value of N 9% is associated with increased mortality risk among patients with type 2 diabetes (Nicholas, Charlton, Dregan, & Gulliford, 2013 ).
Multinomial logistic regressions were then estimated in order to examine the relationship between glycemic control and BMI (kg/m 2 ) levels (normal -18.5 to b25, overweight -25 to b 30, obesity I -30 to b35, obesity II -35 to b40, and obesity III -≥ 40) (World Health Fig. 1 . Inclusion/Exclusion criteria and sample size. Organization, 2015) . The multivariable analyses controlled for person-level characteristics, general health, comorbidities, complications, and antihyperglycemic medication use. Characteristics of interest included age, sex, race, and region of residence. In addition, this study included the percentage of college graduates within the 3-level zip code of patient residence as a proxy for socioeconomic status. General health was proxied by the Charlson Comorbidity Index (CCI) which is constructed by weighting 17 different conditions including peripheral vascular disease, congestive heart failure and malignancy (Quan et al., 2005) . Comorbidities and complications were identified by ICD 9 codes and included the following: diabetic retinopathy (362.01; 362.02; 362.10; 379.23; 250.5x 311; 296.2; 296.3; 296.5-296.7; 300.4 or 296.82; 296.89) . Regression analyses were conducted separately for the T1DM and T2DM cohorts.
As a test of the sensitivity of these findings, the analyses were conducted with glycemic control defined based upon mean HbA1c over the course of the study period rather than highest HbA1c. While use of the highest HbA1c when constructing cutoffs allows for an examination based upon always being at target HbA1c, the use of mean values examines results based upon a less rigorous standard of achieving target HbA1c on average, although HbA1c could be above target for a substantial time period. All analyses were conducted using SAS, version 9.3 (SAS Institute, Cary, NC). A two-tailed p-value b0.05 was considered, a priori, to be statistically significant. Fig. 2 shows there are statistically significant differences between the T1DM and T2DM cohorts, with individuals in the T1DM group more likely to be identified as normal weight (BMI ≥18.5 and b25), while T2DM were more likely to be classified as obese I, obese II, or obese III. Specifically, 47.8% of the T1DM cohort, as compared to 63.4% of the T2DM cohort, was identified as obese.
Results
Tables 1A and 1B present the descriptive statistics for T1DM and T2DM groups, respectively. Results are reported both for the entire cohort and by subgroups defined according highest recorded HbA1c during the 3 years studied. For the cohorts as a whole, results revealed that the largest percentages of T1DM individuals were residents of the midwest (40.0%) and 50.6% were male, while in the T2DM cohort, most individuals were residents of the south (42.4%) and 49.1% were male. The median age was 56 years in the T1DM cohort and 64 in the T2DM cohort. In both cohorts, most patients were Caucasian (64.5% for T1DM and 66.5% for T2DM). The most commonly diagnosed comorbidities were dyslipidemia (77.9% for T1DM and 85.8% for T2DM) and hypertension (73.0% for T1DM and 84.6% for T2DM) in both cohorts. A majority of the T2DM cohort (79.7%) was treated for diabetes with an antihyperglycemic agent. These tables also summarize demographic and clinical characteristics based upon highest recorded HbA1c at any time in the study period. The majority of individuals (91.7% of T1DM and 61.1% of T2DM) were found to have at least one HbA1c test ≥ 7% than target over the 3-year study period.
The multinomial logistic regressions shown in Tables 2A and 2B present the factors quantitatively associated with increased odds of having HbA1c ≥ 7% and b8%, ≥8% and b9%, or ≥ 9% relative to HbA1c b 7% for patients with T1DM and T2DM, respectively. Among patients with T1DM, a BMI classification of overweight or obese was associated with significantly higher probability of having an HbA1c recorded value ≥ 8% and b9% or ≥ 9%. However, while being overweight was associated with a 30% increase in the probability of having an HbA1c ≥ 7% and b 8% compared to having an HbA1c b7% (odds ratio [OR] = 1.301; 95% confidence interval [CI] = 1.078-1.570), there was no statistically significant relationship between obesity (class I, II, or III) and the probability of having an HbA1c ≥7% and b 8%.
The results show that for T2DM patients, compared to normal BMI individuals, being overweight or obese was associated with higher odds of above-target HbA1c. Furthermore, among the T2DM cohort, patients who were obese (class I, II or III) had significantly higher odds of HbA1c above target compared to overweight individuals. For example, overweight individuals were found to have an 18% increase in the probability of having an HbA1c ≥ 7% and b 8% (OR = 1.176; 95% CI 1.132-1.222), a 15% increase in the probability of having an HbA1c ≥ 8% and b9% (OR = 1.148; 95% CI 1.0990-1.210), and a 16% increase in the probability of having an HbA1c ≥ 9% (OR = 1.156; 95% CI 1.099-1.216). In all cases, the odds ratios for obesity were significantly higher. However, there was no significant difference in the probability of having above target glycemic control when comparing different classes of obesity. Table 2A and 2B also shows the individual characteristics associated with greater or lesser odds of having above-target HbA1c. Among patients with T1DM, patients with diabetic retinopathy, diabetic nephropathy, or dyslipidemia were found to have consistently higher odds of above target Hba1c, while those with chronic kidney disease had significantly lower odds of above target HbA1c. In the T1DM cohort, males were found to have a significantly lower probability of having HbA1c ≥8% and b9% or HbA1c ≥ 9%, although for T2DM patients male sex was associated with a higher probability of above target HbA1c. In both the T1and T2DM cohorts, older age was generally associated with an increased probability of having HbA1c ≥7% and b 8% and a lower probability of HbA1c ≥ 9%. Among patients with T2DM, the characteristics generally associated with a higher likelihood of above-target HbA1c were African-American or Asian race (compared to Caucasian), residence in the midwest (compared to the south), use of antihyperglycemic medications, and the presence of comorbid diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, ischemic heart disease, hypertension, or dyslipidemia. In contrast, for patients with T2DM, comorbid chronic kidney disease, anxiety or depression was associated with a significantly lower likelihood of having above-target HbA1c.
As a test of the sensitivity of these results, HbA1c ranges were re-classified based upon mean HbA1c over the three year study period. This less-restrictive definition of above-target HbA1c resulted in 80.6% of the T1DM and 41.7% of the T2DM cohort being identified as having above-target HbA1c (≥7%). For patients with T2DM, these results are generally consistent with the main findings presented in Table 2B . For example, when examining the probability of having a mean HbA1c ≥8% and b 9% compared to having a mean HbA1c of b7%, the odds ratio for BMI classifications of overweight and obesity ranged from 1.148 to 1.604, compared to the sensitivity analysis, where the values ranged from 1.147 to 1.568. However, for patients with T2DM, use of mean HbA1c was not associated with a higher probability of HbA1c N9% among overweight patients (OR = 0.955; 95% CI 0.893-1.021).
Among patients with T1DM, use of mean HbA1c as the dependent variable, rather than highest HBa1c value resulted in two major changes in results. First, with the new definition of above target glycemic control, obesity was associated with a significantly higher probability of having HbA1c ≥ 7% and b 8%, compared to a mean value of b7%. Second, when examining the probability of having a mean HbA1c ≥9% compared to b 7%, being overweight or obese I was not significantly associated with this higher HbA1c target. 
Discussion
This study illustrates the high obesity rates among both T1DM and T2DM patients in the U.S. Correspondingly, the number of patients who do not reach glycemic control is also very high. After controlling for individual's characteristics, general health, antihyperglycemic medication use, and comorbidities and complications, being overweight or obese was generally associated with an increased likelihood of having suboptimal glycemic control in both T1DM and T2DM cohorts. The concurrence of obesity and suboptimal glycemic control is consistent with previous research among older adults (Martins et al., 2012) , and in a predominantly African-American population (El-Kebbi et al., 2003) .
There are potentially many factors behind the challenges in glycemic control and obesity. Robust evidence may require high quality long-term randomized cohort data. Databases containing robust data are scarce, and research from existing databases has limitations to inform the current discussion. Recently several studies have examined socio-demographic, behavioral, and treatmentrelated factors behind glycemic control and generated new insights on the potential factors of glycemic outcomes (Aikens & Piette, 2013; Feldman et al., 2014; McAdam-Marx et al., 2014; Nagrebetsky et al., 2012) .
In a prospective randomized trial where electronic sensor was used to measure prescription adherence, Nagrebetsky et al. (2012) studied the effects of medication adherence on glycemic outcomes in T2DM patients. The study found older age, weight loss and better adherence (≥ 80%), among other factors, predicted lower HbA1c at 1 year. Further investigation found the better glycemic controls in the older patients are not explained by better adherence, but may be partly related to lower BMI. Grandy, Fox, and Hardy (2013) confirmed that adherence improves with weight loss in T2DM population.
McAdam-Marx et al. (2014) compared effects of weight loss and adherence on glycemic control in a health plan population. The study found both weight loss and adherence were associated with glycemic control in T2DM, but weight loss was a stronger predictor than adherence of glycemic control. The literature suggests that there is an indirect effect of weight gain; patients who gain weight may become less adherent to medication therapy. However, the present study has only number of treatments, but no information on medication adherence. However, the results are inconsistent with an examination of the NHANES data which found that mean HbA1c was highest among individuals with normal BMI (Nguyen et al., 2011) . Furthermore, among patients with T2DM, obesity (class I, II, or III) was associated with a significant higher probability of having HbA1c ≥ 7% and b 8%, ≥ 8% and b 9%, or ≥ 9% relative to overweight individuals. This finding suggests that weight changes within the obesity categories may not be as beneficial in maintaining glycemic control compared to moving from obese to overweight or normal BMI.
Research from a prospective study over 12 years found that weight loss among overweight patients with T2DM was associated with a 25% reduction in mortality, as well as a 28% reduction in cardiovascular disease (Williamson et al., 2000) . In contrast, however, the Look AHEAD clinical trial found that weight loss among overweight or obese individuals with T2DM did not reduce the rate of cardiovascular events over 13.5 years (Look AHEAD Research Group, 2013) . The difference in these results may be due to the difference in study design, with patients randomized in clinical trials. Furthermore, there were significant differences in inclusion and exclusion criteria between the two studies, with the prospective study focusing on those age 41-64 with a BMI of at least 27 who had complete data on weight, height, smoking, alcohol use, education, physical activity, and race (Williamson et al., 2000) and the clinical trial study requiring patients to be age 45-75 with a BMI ≥ 25, HbA1c ≤ 11%, systolic blood pressure b 160 mmHg, diastolic blood pressure b 100 mmHg, triglyceride level b 100 mg per deciliter, and the ability to complete a valid maximal exercise test (Look AHEAD Research Group, 2013) . Research has also demonstrated the reduction in microvascular complications (Svensson, Eriksson, & Dahlquist, 2004 ; UK Prospective Diabetes Study (UKPDS) Group, 1998) and medical care charges (Gilmer, O'Connor, Manning, & Rush, 1997 ) associated with improved glycemic control among patients with diabetes as well as a reduction in cardiovascular risk among patients with T1DM (Ferranti et al., 2014) . Taken together, the findings of this research are consistent with previous research which has found significant health and economic benefits associated with weight loss among patients with diabetes who are overweight or obese.
Consistent with guidelines that suggest a target of b 8% may be appropriate for patients with a limited life expectancy (American Diabetes Association, 2015) and from results from an observational study which suggest that a target HbA1c of 8 to 8.9% may be appropriate for the elderly (Yau et al., 2012) , the results of this analysis generally found that as age increased, patients were more likely to have an HbA1c value ≥ 7% and b8% or ≥8% and b 9%, but significantly less likely to have an HbA1c N9%. These results suggest that physicians may be less restrictive regarding HbA1c among the elderly. Among patients with T2DM, Caucasians were found to be more likely to achieve the HbA1c target of b7%. This finding is consistent with previous research which has examined racial disparities in HbA1c among patients with T2DM (Egede et al., 2011; Kirk et al., 2006) . In this study, males with T1DM were found to be significantly less likely to have an above-target HbA1c while males with T2DM were found to be significantly more likely to have above-target HbA1c. This finding is consistent with prior research which has found improved glycemic control among females with T2DM (Kirk et al., 2011) , as well as with research that has found higher HbA1c levels among women with T1DM (Göbl et al., 2012) . Complications of diabetes (diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy) were associated with a higher likelihood of suboptimal glycemic control in both cohorts. This finding is in concert with previous research which has examined the role of comorbidities in general (Egede et al., 2011) , as well as with studies which focused on the relationship between HbA1c and the risk of the development or progression of retinopathy (Diabetes Control and Complications Trial Research Group, 1995), polyneuropathy (El-Salem, Ammari, Khader, & Dhaimat, 2009 ), or nephropathy (Sabanayagam et al., 2009 ). Among patients with both T1DM and T2DM, comorbid CKD was associated with a significant reduction in the odds of having above target HbA1c. Such results may be due to the increased physician monitoring necessitated by worse general health.
Among individuals with T2DM, residents of western states (compared to southern states) were less likely to have suboptimal glycemic control, a result that is consistent with previous research on regional variations in glycemia (Swanson, Potter, Kongable, & Cook, 2011) and obesity rates (Centers for Disease Control and Prevention, 2014a) . In contrast, among the T2DM cohort, people living in the midwest were more likely to have suboptimal glycemic control, a finding which is consistent with national statistics indicating the midwest to be the US region with the lowest rate of healthy (self-described) patients with diabetes (Kirtland, Zack, & Caspersen, 2012) and one of the highest rate of obesity (Centers for Disease Control and Prevention, 2014a) . Individuals with T2DM and comorbid anxiety or depression were significantly less likely to have suboptimal glycemic control; these results are inconsistent with previous research that showed that depression (Papelbaum et al., 2011) and anxiety (Anderson et al., 2002) are associated with worse glycemic control. It may be however, that in this insured population, these patients visit their physician more frequently and hence have the opportunity for more intensive monitoring of their HbA1c. Finally, patients with T2DM who were not taking antihyperglycemic drugs were also generally less likely to have suboptimal glycemic control, a finding which suggests that the lack of antihyperglycemic medication use may indicate that the diabetes is less severe relative to individuals who are treated pharmacologically. However, it should be noted that 22.7% of the individuals with T2DM who were not treated with antihyperglycemic medication had suboptimal glycemic control. The results of this study must be interpreted within the limits of the study design. First, these analyses were based on retrospective, electronic medical data from the physician practice setting, and may therefore be limited in their generalizability. For example, the use of diagnostic codes is not as rigorous as formal assessments and may underrepresent certain conditions. Furthermore, as mentioned previously the database analyzed contains no information on medication adherence, the duration or severity of disease or on various individual behaviors, such as diet and exercise, which may influence outcomes. The analyses may also not have captured all variables that may potentially impact glycemic control, such as blood pressure medication or lipid use, foot and eye examinations, and number of physician visits. In addition, the cross-sectional study design focused on the association between BMI classifications and glycemic control and was unable to allow for a direct examination of causation. Finally, the analyses presented statistically significant differences, some of which resulted from a large sample size. Therefore, an observed statistically significant difference does not necessarily indicate a clinically significant difference.
In conclusion, this real-world retrospective investigation of patients identified with T1DM or T2DM revealed a relationship between BMI and a greater likelihood of having suboptimal glycemic control. This finding quantifies the association between BMI and glycemic control and highlights the potential importance of an individual's characteristics such as age, race, and comorbidities for glycemic control. Results show that for patients with T1DM, patients who are overweight or obese are more likely to have an HbA1c value ≥ 8% and b9% or ≥ 9% and that overweight patients are more likely to have an HbA1c value N7% and b 8%, compared to a value of b 7%. Among patients with T2DM, overweight and obese individuals are more likely than those in normal weight range to have an HbA1c value ≥ 7% and b 8%, ≥ 8% and N9%, or ≥9%, compared to a value of b 7%. However, while obese individuals were more likely than overweight individuals with T2DM to have poor glycemic control, there was no statistical difference in the probability of having above target glycemic control when comparing alternative classes of obesity.
